/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/
/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/
来源:Hazardous Substances Data Bank (HSDB)
毒理性
解毒与急救
/SRP:/ 高级治疗：对于无意识、严重肺水肿或严重呼吸困难的病人，考虑进行口咽或鼻咽气管插管以控制气道。使用气囊面罩装置的正压通气技术可能有益。考虑使用药物治疗肺水肿……。对于严重的支气管痉挛，考虑给予β激动剂，如沙丁胺醇……。监测心率和必要时治疗心律失常……。开始静脉输注D5W /SRP: "保持开放"，最低流量/。如果出现低血容量的迹象，使用0.9%生理盐水（NS）或乳酸林格氏液。对于伴有低血容量迹象的低血压，谨慎给予液体。注意液体过载的迹象……。使用地西泮或劳拉西泮治疗癫痫……。使用丙美卡因氢氯化物协助眼部冲洗……。 /Poisons A and B/
/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/
/LABORATORY ANIMALS: Acute Exposure/ Solvent green 3 produced no skin irritation when applied to intact or abraded skin of rabbits and produced ''minimal'' erythema in the eyes of rabbits.
/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ The quinoline dye 2-(2'-quinolyl)-1,3-indandione or Solvent Yellow 33 (SY) and the anthraquinone dye 1,4-di-p-toluidinoanthraquinone or Solvent Green 3 (SG) are used in many manufactured products including military smoke grenades. During manufacturing, SY or a combination of both SY and SG can be released into the air, exposing factory workers by inhalation to these dye compounds. The potential inhalation toxicity of these compounds was tested by exposing F344/N rats to different concentrations of SY or SY/SG dye mixture (30:70 w/w) for 6 hr/day, 5 days/week for 4 or 13 weeks. In the 4-week studies, rats were exposed to SY aerosols at average concentrations of 10 +/- 5, 51 +/- 10, or 230 +/- 30 mg/cu m (means +/- SD) or SY/SG aerosols at average concentrations of 11 +/- 5, 49 +/- 11, or 210 +/- 50 mg/cu m (means +/- SD). Rats exposed to the highest concentration of SY or SY/SG had body weights that were approximately 8% or 7% less, respectively, than their controls after exposure. Rats exposed to the highest concentration of SY/SG for 4 weeks also had reduced pulmonary gas exchange efficiency, airflow obstruction, mild pulmonary inflammation, slight Type II pulmonary epithelial cell hyperplasia, and proliferation of vacuolated alveolar macrophages. In the 13-week studies, rats were exposed to SY aerosols at average concentrations of 1.0 +/- 0.2, 10.8 +/- 1.8, or 100 +/- 17 mg/ cu m (means +/- SD) or SY/SG aerosols at average concentrations of 1.1 +/- 0.5, 10.2 +/- 3.1, or 101 +/- 23 mg/cu m (means +/- SD). Animals exposed to the highest concentration of SY or SY/SG for 13 weeks had body weights that were approximately 5 or 9% less, respectively, than their controls after exposure and had accumulation of vacuolated alveolar macrophages in lungs. Rats exposed to the highest concentration of SY/SG dye mixture for 13 weeks also had indications of mild pulmonary inflammation and slight Type II pulmonary epithelial cell hyperplasia. Very little SY was found in lungs after any exposures, indicating its clearance from lungs was at a rapid rate. However, significant amounts of the SG component of the SY/SG mixture were detected in lungs after each exposure. Lung clearance half-times of SG from the 13-week exposure were estimated to be approximately 280 days. In summary, neither test material appeared to be highly toxic following inhalation. However, the slightly higher toxicity observed for SY/SG over SY alone is probably related to the longer lung retention of the SG component of the dye mixture.
The respiratory tract deposition, distribution in tissues, metabolism, and excretion of solvent yellow (2-(2'-quinolinyl)-1,3-indandione) were examined in rats after inhalation of (14)C labeled solvent yellow aerosols at 160 nanomoles/liter (nmol/L) solvent yellow in air. Solvent green (1,4-di-p-toluidinoanthraquinone) was also studied. The study was conducted using F344-rats exposed to solvent yellow aerosols or to a mixture of solvent yellow and solvent green (340nmol and 370nmol, respectively) for 60 minutes. Solvent yellow exhibited a half life of 2 to 3 hr, and was thus rapidly cleared from the respiratory tract after either exposure. A minimum estimated half life of 22 days was achieved for the retention of solvent green in the respiratory tract. Samplings of other tissues during the 70hr postexposure period did not indicate the presence of solvent green. A total of 40 to 75 percent of the (14)C present in liver and kidney after either exposure was shown by high pressure liquid chromatography to be metabolites of solvent yellow. The feces proved to be the major pathway for excretion of solvent yellow and its metabolites, accounting for 74 percent of the initial body burden. The excretion half life was 14hr. Fourteen percent of the initial body burden was excreted in the urine with this half life being 10hr. Solvent yellow metabolites accounted for over 90 percent of the (14)C excreted in the urine. Only about 2 percent of the solvent yellow was metabolized to carbon dioxide. Only 10 percent of the initial (14)C deposited in the body remained there after 72hr. ...
In a study on the retention of solvent green 3 in the lungs, rats were given a suspension containing the dye. The authors observed that 87% of the initial dose remained in the lungs 24 hr after exposure.
ALPHA-AMINO ACID DERIVATIVES FOR IMPROVING SOLUBILITY
申请人：Rudolph Thomas
公开号：US20110039924A1
公开（公告）日：2011-02-17
The invention relates to the use of α-amino acid derivatives for improving the solubility of poorly soluble substances in water or aqueous solutions and to mixtures and preferred preparations.
这项发明涉及使用α-氨基酸衍生物来提高水或水溶液中难溶物质的溶解度，以及混合物和优选制剂。
USE OF FLAVONOIDS
申请人：Rudolph Thomas
公开号：US20090317342A1
公开（公告）日：2009-12-24
The present invention relates to the use of at least one flavonoid for odour improvement and/or odour stabilisation, and to corresponding compositions and the preparation thereof.
本发明涉及至少一种黄酮类化合物用于改善气味和/或稳定气味，以及相应的组合物及其制备方法。
COLORING AGENTS AND METHODS OF USE THEREOF
申请人：Living Proof, Inc.
公开号：US20160106648A1
公开（公告）日：2016-04-21
Dyes, compositions comprising dyes and methods for using the same are provided.
The invention relates to complexes of certain chromone derivatives, to compositions which comprise such derivatives, to corresponding processes for the preparation of the chromone derivatives or of compositions comprising same, and to the use thereof, in particular for the care, maintenance or improvement of the general state of the skin or hair.
